Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. It is a promising compound for the therapy and prophylaxis of all forms of theileriosis. Buparvaquone has been shown to have anti-leishmanial activity in vitro
Buparvaquone is used in the treatment of theileriosis (east coast fever, corridor disease, Zimbabwean theileriosis, tropical theileriosis, tropical theileriosis) caused by intracellular protozoan parasites Theileria parva theileria parabovis, Theileria parva parasites Theileria parva theileria mutants and Theleria orientalis sergenti in cattle.
buparvaquone is active against the schizontal and piroplasm stages of theileria spp. and can be used during the incubation period of the disease or when clinical signs are apparent.
Each ml contains Buparvaquone 50 mg. It is indicated for treatment of theileriosis.